1850 Safety of everolimus plus exemestane in elderly patients with Hormone-Receptor-Positive (HR+), HER2- locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors (NSAIs): BALLET (CRAD001YIC04). (September 2015) - Neven, P.; Generali, D.; Ciruelos, E.M.; Lang, I.; Gavila, J.G.; Bighin, C.; Borms, M.; Conte, P.; Montemurro, F.; Sartori, D.; Lee, T.V.; Camozzi, M.; et al.